Study of Romiplostim for Chemotherapy Induced Thrombocytopenia

NCT02052882 | Completed Phase 2 Results

• 1 other identifier: 13-132
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 6

Brief Summary

This study is to determine if using weekly romiplostim injections will improve the patient's platelet count more effectively than simply waiting for the platelets to improve on its own, and if romiplostim will also allow the patient to receive at least 2 further cycles of chemotherapy without thrombocytopenia.

Conditions

Isolated Chemotherapy-induced Thrombocytopenia

Keywords

Romiplostim; Thrombocytopenia; 13-132

Outcome Measures

Primary Outcomes (1)

• Percentage of Participants Who Achieved Platelet Counts of ≥ 100,000/mcL

  The primary therapeutic response is assessed by the platelet count within 3 weeks of treatment.

  within 3 weeks after treatment

Secondary Outcomes (1)

• Number of Participants Evaluated for Toxicity

  1 year

Study Arms (1)

Romiplostim

EXPERIMENTAL

All patients will begin weekly romiplostim at 2 mcg/kg, subcutaneously. The romiplostim dose will be titrated on weekly CBC/platelet counts. For titration purposes, the target platelet count is 150,000-200,000/mcL. Treatment can be held up to 16 days if a patient develops an intercurrent medical illness or symptom that is unrelated to study drug therapy. Treatment may be held up to 20 days if the patient unavailable for non- medical reasons, such as vacation or travel.

Biological: romiplostim

Interventions

romiplostim BIOLOGICAL

Romiplostim

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Patients (18 years of age or greater) with active non-hematological cancer:
• A. The patients have previously received a chemotherapy regimen including one or more of the following agents:
• Nucleoside Analogue, including gemcitabine and fluorouracil
• Carboplatin or cisplatin
• Anthracycline
• Alkylating agent
• Other chemotherapy agents with thrombocytopenia as known common toxicity.
• \. Patients who have not had any cytotoxic chemotherapy within 14 days of beginning the study.
• \. Thrombocytopenia:.
• A. Defined as platelet count \<100,000/mcL.
• B. The patient will have had at least 2 CBCs with platelet counts \<100,000/mcL separated by at least 4 weeks, and no platelet count ≥100,000/mcL in the prior 6 week period, despite (1) delay, or (2) modification of chemotherapeutic regimen.
• C. A platelet count of \>100,000/mcL, that follows within 7 days of a platelet transfusion, will not make the patient ineligible, as long as one or more subsequent platelet counts confirms thrombocytopenia (\<100,000/mcL).
• D. Patients have undergone bone marrow aspirate and biopsy or peripheral blood test in the prior 3 months without evidence of leukemia or myelodysplasia by fluorescent in situ-hybridization (FISH) E. Dysplastic changes, based on morphology only, will not exclude the patient if FISH panel for MDS is normal.
• KPS ≥ 50 or ECOG performance status ≤2 .
• Ability to provide written informed consent.

You may not qualify if:

• Patients with history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases.
• Patients with known bone metastases, with evidence of corticol bone damage/lytic lesions/blastic lesions on standard imaging studies (CT/MR)
• Anemia (Hgb \<8.0 gm/dl) or leukopenia (absolute neutrophil count (ANC) \<1,000/mcL). Use of red cell transfusions, erythropoietin, or G-CSF, as ordered by the managing oncology service, is acceptable and does not preclude participation.
• Patients with underlying liver disease, such as cirrhosis or chronic hepatitis, and do not have primary or metastatic cancer in the liver will be excluded if ALT/AST \>3X ULN or Total Bili \>3X ULN. In the presence of primary or metastatic liver cancer, patients will be excluded if ALT/AST \>5X ULN or Total Bili \>5X ULN
• Patients with a history of a prior symptomatic venous thrombotic event such, as DVT or pulmonary embolism and symptomatic arterial thrombotic events such as myocardial infarction, ischemic cerebral vascular accident or transient ischemic attack will be ineligible if they have not tolerated anticoagulation therapy. If patients remain on anticoagulation, or have completed the prescribed course of anticoagulation, they will be eligible for enrollment. A venous thrombotic event associated with a central venous catheter will not make the patient ineligible.
• Serious concomitant medical condition that could interfere with the conduct of the clinical trial, such as unstable angina, renal failure requiring hemodialysis, or active infection requiring IV antibiotics
• Pregnant women/lactating mothers
• Patients unwilling to use contraception.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Amgen: collaborator

Study Sites (6)

Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, 07920, United States

Location

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Cancer Center @ Suffolk

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Publications (1)

• Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia. J Clin Oncol. 2019 Nov 1;37(31):2892-2898. doi: 10.1200/JCO.18.01931. Epub 2019 Sep 23.

  PMID: 31545663 DERIVED

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Thrombocytopenia

Interventions

romiplostim

Condition Hierarchy (Ancestors)

Blood Platelet Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Cytopenia

Results Point of Contact

• Title: Dr. Cy Wilkins, MD
• Organization: Memorial Sloan Kettering Cancer Center

wilkinsc@mskcc.org

646-608-3720

Study Officials

• Cy Wilkins, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 30, 2014
• First Posted: February 3, 2014
• Study Start: January 30, 2014
• Primary Completion: November 13, 2023
• Study Completion: November 13, 2023
• Last Updated: December 27, 2024
• Results First Posted: December 27, 2024

Record last verified: 2023-11

Locations

US (6)